Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Wendy K. Alderton"'
Autor:
J D Best, Wendy K Alderton
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 3, Pp 567-576 (2008)
J D Best, Wendy K AldertonSummit (Cambridge) Ltd., Beach Drive, Cambridge, UKAbstract: As the population ages, there is a growing need for effective therapies for the treatment of neurological diseases. A limited number of therapeutics are currently
Externí odkaz:
https://doaj.org/article/c8ffa0def81f44648c917d916be30c05
Autor:
Wendy K. Alderton, J.C. Barnes, Usha Menon, Hector C. Keun, Ian Jacobs, Lauren Harper, Sophia Apostolidou, Gabriel N. Valbuena, Rhiannon Roberts
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Understanding the normal temporal variation of serum molecules is a critical factor for identifying useful candidate biomarkers for the diagnosis and prognosis of chronic disease. Using small RNA sequencing in a longitudinal study of 66 women with no
Autor:
Suzanne A. Eccles, Pauline Moore, Lori Friedman, Paul A. Clarke, Stewart J. Baker, Olivero Alan G, Gary Box, Anthony Robson, Paul Workman, Khatereh Ahmadi, Laurent Salphati, Nahid Saghir, Giles Pergl-Wilson, Irina Chuckowree, Mark H. Ultsch, Wendy K. Alderton, Marketa Zvelebil, Florence I. Raynaud, Sukhjit Sohal, Arumugam Kugendradas, Christian Wiesmann, Adrian Folkes, Sonal Patel, Letitia Lensun, Angela Hayes, Timothy Hancox, Stephen J. Shuttleworth, Alexander Zhyvoloup, Heidi J.A. Wallweber, Paul Depledge, Melanie Valenti, Sonia Alix, Nan Chi Wan, Jodie Pang
Publikováno v:
Journal of Medicinal Chemistry. 51:5522-5532
Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/ Akt signaling pathway in a wide variety of tumors. A series of thieno[3,2-d]pyrimidine derivatives were prepared and evaluated as inhibitors of
Autor:
Wendy K Alderton, J D Best
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 3, Pp 567-576 (2008)
Neuropsychiatric Disease and Treatment
Neuropsychiatric Disease and Treatment
J D Best, Wendy K AldertonSummit (Cambridge) Ltd., Beach Drive, Cambridge, UKAbstract: As the population ages, there is a growing need for effective therapies for the treatment of neurological diseases. A limited number of therapeutics are currently
Publikováno v:
Biochemical Journal. 358:201-208
The binding of CO to the murine inducible nitric oxide synthase (iNOS) oxygenase domain has been studied by laser flash photolysis. The effect of the (6R)-5,6,7,8-tetrahydro-l-biopterin (BH4) cofactor l-arginine and several Type I l-arginine analogue
Publikováno v:
Biochemical Journal. 357:593-615
This review concentrates on advances in nitric oxide synthase (NOS) structure, function and inhibition made in the last seven years, during which time substantial advances have been made in our understanding of this enzyme family. There is now inform
Publikováno v:
Biochemical Journal. 332:195-201
Nitric oxide synthases (NOS) have a bidomain structure comprised of an N-terminal oxygenase domain and a C-terminal reductase domain. The oxygenase domain binds haem, (6R)-5,6,7,8-tetrahydro-l-biopterin (tetrahydrobiopterin) and arginine, is the site
Publikováno v:
European Journal of Biochemistry. 233:880-885
Recombinant ricin A chain was irreversibly modified by Procion blue MX-R, a dichlorotriazinyl analogue of Cibacron blue F3G-A, at pH 7.5 and 4 degrees C in 90 h with over 95% loss of activity in an in vitro translation assay. The presence of total ye
Publikováno v:
Journal of Chromatography A. 677:289-299
Immunotoxins, such as those based on ricin A chain, must be rigorously purified before they can be administered in vivo. The work described in this paper investigates the interaction between recombinant ricin A chain and several triazine dyes and oth
Autor:
Janette A. Thomas, Burton Steven J, Wendy K. Alderton, Jennifer M. Pitts, Nicolas P. Burton, Christopher R. Lowe
Publikováno v:
Trends in Biotechnology. 10:442-448
Affinity chromatography has been extensively refined over the past few years to meet the more stringent criteria being placed on recombinant proteins as therapeutic products. New developments in the design of selective and stable ligands for affinity